Medtronic begins European launch of brain signal-recording neurostimulator for Parkinson's disease

3D brain against purple background
The addition of real-world brain signal data will allow physicians to more precisely customize therapies. (alex-mit/iStock/Getty Images Plus)

Medtronic received a CE mark for a deep brain stimulation system that can not only deliver electrical therapy but also record the brain’s signals in order to adjust and personalize treatment.

The Percept PC neurostimulator is designed to help isolate, track and analyze the responses of people with neurological disorders such as Parkinson’s disease and correlate their objective brain readings with patient-recorded events regarding symptoms or treatment side effects.

Currently under review at the FDA, the device was approved in the EU for people with Parkinson’s, essential tremor and primary dystonia as well as epilepsy and obsessive-compulsive disorder. Medtronic said its first implantations will begin next week in western Europe before launching in additional regions.  

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

RELATED: Medtronic launches brain-stim programmer on a Samsung phone

The addition of deep brain stimulation to treatment has been shown to improve motor function in patients with Parkinson’s disease compared to medication alone, but those therapeutic decisions are typically made on patient-reported information. The addition of real-world brain signal data will allow more precise and customized guidance, according to Medtronic. 

“Patients are empowered to take an active role in their therapy, and physicians can deliver data-driven, personalized therapy that fits the needs of today’s patients, now and in the future,” said Mike Daly, vice president and general manager of Medtronic’s brain modulation business. 

RELATED: Medtronic submits rechargeable sacral neurostimulation device for FDA approval

Additionally, the Percept PC system includes MRI-safe labeling for full-body scans at 1.5 and 3 Tesla and improved battery life with a smaller design compared to Medtronic’s Activa PC neurostimulator. It can also be connected to a patient programming application via a custom Samsung mobile device.

Suggested Articles

A COVID-19 antibody diagnostic developed through a joint venture between Mount Sinai Health System and RenalytixAI has been authorized by the FDA.

Researchers at Northwestern University have trained an AI algorithm to automatically detect the signs of COVID-19 on a basic X-ray of the lungs.

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.